Arcus Biosciences Inc. Stock News

Arcus Biosciences (NYSE:RCUS) had its price target lifted by investment analysts at SVB Leerink from $68.00 to $100.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage presently has an outperform rating on the stock. SVB Leerinks price objective points to a potential upside of 110.30% from the []

Arcus Biosciences, Inc. (NYSE:RCUS)s share price traded up 4.8% on Friday after Wedbush raised their price target on the stock from $52.00 to $67.00. Wedbush currently has an outperform rating on the stock. Arcus Biosciences traded as high as $45.62 and last traded at $45.62. 2,984 shares changed hands during trading, a decline of 99% []

Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).

Analysts forecast that Arcus Biosciences, Inc. (NYSE:RCUS) will report sales of $9.20 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Arcus Biosciences earnings. The lowest sales estimate is $8.10 million and the highest is $10.00 million. Arcus Biosciences reported sales of $9.49 million in the same quarter last []

Arcus Biosciences, Inc. (NYSE:RCUS) shares hit a new 52-week high on Thursday after SVB Leerink raised their price target on the stock from $68.00 to $100.00. SVB Leerink currently has an outperform rating on the stock. Arcus Biosciences traded as high as $42.99 and last traded at $42.59, with a volume of 63447 shares. The []

Gilead Sciences Inc (NASDAQ: GILD ) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS ) portfolio, including both anti-TIGIT molecules, domvanalimab, and AB308, as well as etrumadenant and quemliclustat. Under the terms Agreement, Arcus will receive option payments totaling $725 million for the three options that Gilead is exercising today. The parties will … Full story available on Benzinga.com

Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.

Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.

The stock price of Arcus Biosciences Inc (NYSE: RCUS) increased by over 10% pre-market today. This is why it happened.

Shares of Arcus Biosciences Inc. RCUS, -1.10% rocketed 21% in premarket trading Thursday, after Gilead Sciences Inc. GILD, +0.85% said it's exercising options to three programs in the company's clinic

Related Stocks: RCUS , GRTS , RNA , NRIX , DSGN , ODT , GLPG , PTGX , TNGX , ERAS , IMVT , BLUE , TBIO , KYMR , ARVN , BCEL , KDNY , ZNTL ,

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensa

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compens

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management w